Internationale Publikationen
Hier stellen wir eine Auswahl wissenschaftlicher Veröffentlichungen zur Verfügung, die im Zusammenhang mit der IOZK-Immuntherapie stehen.
Sie können mit Hilfe der Filter eine Auswahl nach Tumorarten und Methoden treffen, oder Suchbegriffe eingeben.
Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH
The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis
Mechanisms of murine dendritic cell antitumor dysfunction in aging
Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer – a phase II study
Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer
Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol
Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice
Dendritic cells in the skin–potential use for melanoma treatment
Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection
Recent advances in cancer vaccines: an overview
Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells
Tumor infection by oncolytic reovirus primes adaptive antitumor immunity
Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study
Radiotherapy and hyperthermia for treatment of primary locally advanced cervix cancer: results in 378 patients
[Activation of anti-tumor cytotoxic T lymphocytes by fusion of human dendritic cells and melanoma cells]
Dendritic cell vaccines for the treatment of prostate cancer
Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo
The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells
Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma
Dendritic cells pulsed with keyhole limpet hemocyanin and cryopreserved maintain anti-tumor activity in a murine melanoma model